Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors

Fineline Cube Apr 14, 2026
Company Deals

Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M

Fineline Cube Apr 14, 2026
Company Deals

Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration

Fineline Cube Apr 14, 2026
Company Deals

IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers

Fineline Cube Apr 13, 2026
Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Fineline Cube Apr 13, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History

Fineline Cube Apr 14, 2026
Company Drug

Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years

Fineline Cube Apr 14, 2026
Company Deals

Luye Pharma’s Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil

Fineline Cube Nov 25, 2024

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955),...

Company Deals

Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million

Fineline Cube Nov 25, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced revisions to its private placement plan,...

Company

Danish Pharma H. Lundbeck A/S Sees Strong Q3 and Q1-Q3 2024 Financial Results

Fineline Cube Nov 25, 2024

Denmark-based pharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has revealed its financial results for the...

Policy / Regulatory

National Allied Procurement Office Announces Round 10 VBP Tender Program with New Rules

Fineline Cube Nov 25, 2024

The National Allied Procurement Office has released a notification regarding Round 10 of the national...

Policy / Regulatory

Jiangsu Chia Tai Fenghai’s ALS Treatment FHND1002 Selected for CDE’s Patient-Centered Care Plan

Fineline Cube Nov 25, 2024

China’s Center for Drug Evaluation (CDE) has announced its intention to include Jiangsu Chia Tai...

Company Medical Device

Acotec Scientific Holdings Receives NMPA Approval for Thrombus Aspiration Catheter Support Tube

Fineline Cube Nov 25, 2024

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval...

Company Drug

Henlius Biotech Initiates Phase III Study for HLX22 in Gastric Cancer Treatment

Fineline Cube Nov 25, 2024

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the dosing of the first patient...

Policy / Regulatory

China’s NHC Sets Sights on Enhancing Grassroots Drug Management and Access

Fineline Cube Nov 25, 2024

The National Health Commission (NHC) has issued a set of opinions designed to accelerate the...

Company Drug

MicroPort Scientific Corp.’s BonaFire Receives NMPA Approval as First Whole-Body MRI Safety Pacing Electrode Lead

Fineline Cube Nov 25, 2024

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...

Company Drug

Base Therapeutics’ NK510 Receives US FDA Clearance for Advanced Solid Tumor Studies

Fineline Cube Nov 25, 2024

Shanghai-based cell therapy specialist Base Therapeutics has achieved clearance from the US Food and Drug...

Company Deals

Merck KGaA Partners with NTU Singapore to Drive Digital Transformation with Trust Technology

Fineline Cube Nov 25, 2024

Merck KGaA (NYSE: MRK) has entered into a Memorandum of Understanding with the Digital Trust...

Company Drug

GSK’s Arexvy Receives MHLW Approval for Expanded RSV Indication in Japan

Fineline Cube Nov 25, 2024

UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that Japan’s Ministry of Health, Labour...

Company Drug

China Resources Double-Crane Gets NMPA Approval for Semaglutide Biosimilar Clinical Trial

Fineline Cube Nov 25, 2024

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced that it has received clinical...

Company Drug

J&J Submits sBLA to FDA for Subcutaneous Tremfya Regimen in Ulcerative Colitis

Fineline Cube Nov 25, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to...

Company Drug

Servier’s Vorasidenib Approved in Boao Lecheng Medical Zone for Diffuse Gliomas

Fineline Cube Nov 25, 2024

French pharmaceutical company Servier’s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor,...

Company Drug

Leads Biolabs’ LBL-024 Earns FDA Orphan Drug Designation for Neuroendocrine Cancer

Fineline Cube Nov 25, 2024

China-based Leads Biolabs Inc. has announced that it has obtained Orphan Drug Designation (ODD) from...

Company Drug

Signet Therapeutics’ SIGX1094 Earns Orphan Drug Designation for Gastric Cancer from FDA

Fineline Cube Nov 25, 2024

China-based Signet Therapeutics has announced that it has received Orphan Drug Designation (ODD) from the...

Company Deals

Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange

Fineline Cube Nov 25, 2024

China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to...

Company Drug

MSD Partners with Cancer Foundation of China for HPV Vaccine Donation Program

Fineline Cube Nov 25, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a donation agreement with the...

Company Drug

Sciwind Biosciences’ Ecnoglutide Accepted for Review by China’s NMPA for Type 2 Diabetes

Fineline Cube Nov 25, 2024

China-based Sciwind Biosciences Co., Ltd has announced that the National Medical Products Administration (NMPA) has...

Posts pagination

1 … 244 245 246 … 650

Recent updates

  • GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors
  • Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M
  • Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration
  • Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History
  • Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors

Company Deals

Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M

Company Deals

Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration

Company Drug

Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.